학술논문
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Document Type
Article
Author
Wagemann, O.; Liu, H.; Clifford, D.B.; Supnet-Bell, C.; Santacruz, A.M.; Aschenbrenner, A.J.; Hassenstab, J.J.; Ibanez, L.; Perrin, R.J.; Li, Y.; Morris, J.C.; Llibre-Guerra, J.; Bateman, R.J.; McDade, E.; Levin, J.; Wang, G.; Shi, X.; Xiong, C.; Bittner, T.; Scelsi, M.A.; Farlow, M.R.; Benzinger, T.L.S.; Gordon, B.A.; Coalier, K.A.; Cruchaga, C.; Lah, J.J.; Berman, S.B.; Roberson, E.D.; Van Dyck, C.H.; Galasko, D.; Gauthier, S.; Hsiung, G.-Y.R.; Brooks, W.S.; Pariente, J.; Mummery, C.J.; Fox, N.C.; Day, G.S.; Ringman, J.M.; Mendez, P.C.; St. George-Hyslop, P.; Suzuki, K.; Okhravi, H.R.; Chhatwal, J.; Jucker, M.; Sims, J.R.; Holdridge, K.C.; Proctor, N.K.; Yaari, R.; Andersen, S.W.; Mancini, M.
Source
In: JAMA Neurology . (JAMA Neurology, 10 June 2024, 81(6):582-593)
Subject
Language
English
ISSN
21686157
21686149
21686149